Understanding Peripheral Vascular Diseases in Type 2 Diabetes Patients: Causes and

Complications

Poornima Rai, Research Scholar, Malwanchal University, Indore

Dr.Sherin P K ,Research Supervisor, Malwanchal University ,Indore

Introduction

Peripheral vascular diseases (PVD) present a significant health concern among individuals
diagnosed with type 2 diabetes mellitus (T2DM). The coexistence of T2DM and PVD
significantly exacerbates health risks, leading to severe complications and poorer prognoses.
Understanding the causes and complications of PVD in T2DM patients is crucial for effective
management and prevention strategies. This article delves into the multifactorial etiology of
PVD in T2DM and explores the complications that arise from this comorbidity.

Causes of Peripheral Vascular Diseases in Type 2 Diabetes Patients

1. Hyperglycemia and Insulin Resistance: Chronic hyperglycemia and insulin

resistance, hallmark features of T2DM, contribute significantly to the development of
PVD. Elevated blood glucose levels lead to endothelial dysfunction, promoting
atherosclerosis and impairing vasodilation, thereby increasing the risk of peripheral
artery disease (PAD).
2. Dyslipidemia: T2DM is often accompanied by dyslipidemia, characterized by
elevated levels of triglycerides and low-density lipoprotein cholesterol (LDL-C) and
reduced levels of high-density lipoprotein cholesterol (HDL-C). Dyslipidemia
accelerates atherosclerosis, narrowing blood vessels and impeding blood flow to
peripheral tissues.
3. Hypertension: High blood pressure is prevalent in T2DM patients and serves as an
independent risk factor for PVD. Hypertension contributes to endothelial damage,
arterial stiffness, and increased vascular resistance, exacerbating the progression of
peripheral vascular complications.
4. Obesity: Obesity is intricately linked with T2DM and is a significant contributor to
PVD development. Adipose tissue secretes pro-inflammatory cytokines and

313
2024, IRJEdT Volume: 06, Issue: 04 | April-2024
 adipokines, promoting a chronic inflammatory state conducive to atherosclerosis and
endothelial dysfunction.
5. Smoking: Tobacco smoking is a modifiable risk factor that significantly amplifies the
risk of PVD in T2DM patients. Smoking promotes vasoconstriction, oxidative stress,
and endothelial damage, accelerating the progression of atherosclerosis and PAD.
6. Genetic Predisposition: Certain genetic factors predispose individuals to both T2DM
and PVD. Genetic variations affecting lipid metabolism, vascular function, and
inflammation pathways increase susceptibility to these conditions.

Complications of Peripheral Vascular Diseases in Type 2 Diabetes Patients

1. Peripheral Artery Disease (PAD): PAD is a common complication of PVD in

T2DM patients, characterized by narrowing or blockage of arteries supplying blood to
the extremities. PAD manifests as intermittent claudication, ulceration, gangrene, and
ultimately limb amputation if left untreated.
2. Critical Limb Ischemia (CLI): CLI represents an advanced stage of PAD, marked
by severe arterial occlusion and inadequate blood supply to the lower limbs. T2DM
patients with CLI face a heightened risk of limb loss, infections, and impaired wound
healing, significantly impacting quality of life.
3. Diabetic Foot Ulcers (DFUs): Neuropathy and peripheral arterial insufficiency
predispose T2DM patients to DFUs, non-healing ulcers that commonly affect the feet.
DFUs are prone to infection and may progress to osteomyelitis, necessitating
aggressive wound management and antibiotic therapy.
4. Cardiovascular Complications: PVD in T2DM patients significantly augments the
risk of cardiovascular events such as myocardial infarction, stroke, and coronary
artery disease. The systemic nature of atherosclerosis underscores the importance of
comprehensive cardiovascular risk reduction strategies in diabetic individuals.
5. Reduced Quality of Life: The debilitating symptoms and functional limitations
associated with PVD adversely affect the quality of life in T2DM patients. Mobility
impairment, chronic pain, and psychological distress contribute to diminished
physical and emotional well-being.
6. Increased Mortality Risk: T2DM patients with coexisting PVD face substantially
higher mortality rates compared to those without vascular complications. The

314
2024, IRJEdT Volume: 06, Issue: 04 | April-2024
 synergistic effects of diabetes and PVD on cardiovascular mortality emphasize the
need for aggressive risk factor modification and timely interventions.

Conclusion

Peripheral vascular diseases pose formidable challenges in the management of type 2 diabetes
mellitus. The intricate interplay of metabolic, vascular, and lifestyle factors contributes to the
development and progression of PVD in diabetic individuals. Recognizing the causes and
complications of PVD in T2DM patients is paramount for implementing targeted preventive
measures, optimizing glycemic and cardiovascular control, and mitigating adverse outcomes.
Multidisciplinary approaches encompassing lifestyle modifications, pharmacotherapy,
revascularization procedures, and wound care are essential components of comprehensive
management strategies aimed at preserving limb function and enhancing the overall well-
being of diabetic individuals with peripheral vascular diseases.

Reference

1. Cost-effective management of diabetes mellitus. Motala AA, Pirie FJ, Rauff S, Bacus HB.
https://pubmed.ncbi.nlm.nih.gov/16774016/ Ethn Dis. 2006;16:0–84.

2. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific

statement from the American Heart Association and the American Diabetes Association. Buse
JB, Ginsberg HN, Bakris GL, et al. Circulation. 2007;115:114–126.

3. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and
2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Saeedi P,
Petersohn I, Salpea P, et al. Diabetes Res Clin Pract. 2019;157:107843.

4. Diabetes Prevalence Survey of Pakistan (DPS-PAK): prevalence of type 2 diabetes mellitus

and prediabetes using HbA1c: a population-based survey from Pakistan. Aamir AH, Ul-Haq
Z, Mahar SA, et al. BMJ Open. 2019;9:0.

5. Peripheral artery disease in patients with diabetes: epidemiology, mechanisms, and

outcomes. Thiruvoipati T, Kielhorn CE, Armstrong EJ. World J Diabetes. 2015;6:961–969.

6. Peripheral artery disease among Indigenous Canadians: what do we know? Bonneau C,

Caron NR, Hussain MA, Kayssi A, Verma S, Al-Omran M. Can J Surg. 2018;61:305–310.

315
2024, IRJEdT Volume: 06, Issue: 04 | April-2024
7. Update on peripheral artery disease: epidemiology and evidence-based facts. Shu J,
Santulli G. Atherosclerosis. 2018;275:379–381.

8. Peripheral arterial disease in women: an overview of risk factor profile, clinical features,
and outcomes. Jelani QU, Petrov M, Martinez SC, Holmvang L, Al-Shaibi K, Alasnag M.
https://link.springer.com/article/10.1007/s11883-018-0742-x. Curr Atheroscler Rep.
2018;20:40.

9. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. Hiatt WR, Fowkes
FG, Heizer G, et al. N Engl J Med. 2017;376:32–40. [PubMed] [Google Scholar]

10. Risk factors of peripheral arterial disease: a case control study in Sri Lanka. Weragoda J,
Seneviratne R, Weerasinghe MC, Wijeyaratne SM.
https://link.springer.com/article/10.1186/s13104-016-2314-x. BMC Res Notes. 2016;9:508.

11. Treatment of dyslipidemia in patients with type 2 diabetes. Vijayaraghavan K.

https://lipidworld.biomedcentral.com/articles/10.1186/1476-511X-9-144. Lipids Health Dis.
2010;9:144.

12. Pathophysiology of chronic limb ischemia. Simon F, Oberhuber A, Floros N, Düppers P,

Schelzig H, Duran M. https://link.springer.com/article/10.1007/s00772-018-0380-1.
Gefasschirurgie. 2018;23:13–18.

13. Influence of smoking on incidence and prevalence of peripheral arterial disease.

Willigendael EM, Teijink JA, Bartelink ML, et al. J Vasc Surg. 2004;40:1158–1165.

14. Vascular disease in the lower limb in type 1 diabetes. Edmonds M. Cardiovasc Endocrinol
Metab. 2019;8:39–46.

15. Peripheral vascular disease risk in diabetic individuals without coronary heart disease.
Wilcox T, Newman JD, Maldonado TS, Rockman C, Berger JS. Atherosclerosis.
2018;275:419–425.

16. Peripheral vascular diseases; noninvasive approach for evaluation and treatment. Malik
GA, Qureshi KK, Ahmad I. Professional Med J. 2007;14:134–143

316
2024, IRJEdT Volume: 06, Issue: 04 | April-2024